Abstract
Cytokines are involved in osteoarthritis (OA) at several levels. They are involved in primary cartilage damage, but also in synovial activation that is observed in osteoarthritic joints. From in vitro studies and animal models for OA, several cytokines have been identified that are potential targets for OA therapy. Two promising targets are the destructive cytokine Interleukin-1 (IL-1) and the anabolic growth factor transforming growth factor (TGF)β and these will be discussed in more detail. Inhibition of IL-1 has been proven to result in amelioration of osteoarthritis-like pathology in animal models and the role of IL-1 is substantiated in studies in IL-1 deficient mice. In contrast, application of the anabolic growth factor TGFβ may provide an alternative approach to promote cartilage integrity and repair. TGFβ is a potent stimulator of chondrocyte matrix production, and therefore has a potency to repair already damaged cartilage. However, TGFβ induces tissue fibrosis and osteophytes at the joint margins and can only be applied to promote cartilage repair when these side effects can be blocked. This appears possible with concomitant, compartmentalized application of selective inhibitors of TGFβ in soft tissues, using local gene therapy with inhibitory Smad 6 and 7. Since OA is often limited to a few joints, local gene therapy may provide a suitable way to treat OA patients. Depending on the phenotype of a particular OA patient, e.g. with or without marked synovial activation, treatment may be focused mainly on suppression of catabolism or stimulation of anabolism, but combination therapy seems most warranted.
Keywords: osteoarthritis, cartilage, cytokines, Interleukin-1, Interleukin-1 receptor antagonist, Transforming Growth Factor beta, SMAD, Gene therapy
Current Drug Targets
Title: Cytokine Targeting in Osteoarthritis
Volume: 8 Issue: 2
Author(s): Arjen B. Blom, Peter M. van der Kraan and Wim B. van den Berg
Affiliation:
Keywords: osteoarthritis, cartilage, cytokines, Interleukin-1, Interleukin-1 receptor antagonist, Transforming Growth Factor beta, SMAD, Gene therapy
Abstract: Cytokines are involved in osteoarthritis (OA) at several levels. They are involved in primary cartilage damage, but also in synovial activation that is observed in osteoarthritic joints. From in vitro studies and animal models for OA, several cytokines have been identified that are potential targets for OA therapy. Two promising targets are the destructive cytokine Interleukin-1 (IL-1) and the anabolic growth factor transforming growth factor (TGF)β and these will be discussed in more detail. Inhibition of IL-1 has been proven to result in amelioration of osteoarthritis-like pathology in animal models and the role of IL-1 is substantiated in studies in IL-1 deficient mice. In contrast, application of the anabolic growth factor TGFβ may provide an alternative approach to promote cartilage integrity and repair. TGFβ is a potent stimulator of chondrocyte matrix production, and therefore has a potency to repair already damaged cartilage. However, TGFβ induces tissue fibrosis and osteophytes at the joint margins and can only be applied to promote cartilage repair when these side effects can be blocked. This appears possible with concomitant, compartmentalized application of selective inhibitors of TGFβ in soft tissues, using local gene therapy with inhibitory Smad 6 and 7. Since OA is often limited to a few joints, local gene therapy may provide a suitable way to treat OA patients. Depending on the phenotype of a particular OA patient, e.g. with or without marked synovial activation, treatment may be focused mainly on suppression of catabolism or stimulation of anabolism, but combination therapy seems most warranted.
Export Options
About this article
Cite this article as:
Blom B. Arjen, van der Kraan M. Peter and van den Berg B. Wim, Cytokine Targeting in Osteoarthritis, Current Drug Targets 2007; 8 (2) . https://dx.doi.org/10.2174/138945007779940179
DOI https://dx.doi.org/10.2174/138945007779940179 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Allosteric Inhibitors of Bcr-Abl: Towards Novel Myristate-Pocket Binders
Current Pharmaceutical Biotechnology Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis
Current Pharmaceutical Design Co-opting Functions of Cholinesterases in Neural, Limb and Stem Cell Development
Protein & Peptide Letters ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Novel Antibacterial Agents: An Emergent Need to Win the Battle Against Infections
Mini-Reviews in Medicinal Chemistry Discovery of Selective Small Molecular TACE Inhibitors for the Treatment of Rheumatoid Arthritis
Current Medicinal Chemistry Anti-inflammatory Action of Green Tea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry LncRNA, Important Player in Bone Development and Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Nuclear Factor-κB in Inflammatory Lung Disease
Inflammation & Allergy - Drug Targets (Discontinued) Cytochrome P450 Structure, Function and Clinical Significance: A Review
Current Drug Targets Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Interferon-beta Inhibits Th17 Cell Differentiation in Patients with Multiple Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Application of Quantum Dots in Drug Delivery
Nanoscience & Nanotechnology-Asia Medicinal Chemistry of 2,2,4-Substituted Morpholines
Current Medicinal Chemistry The Relationship Between FoxP3 and SOCs3 Gene Expressions and Disease Activity in Rheumatoid Arthritis
Current Rheumatology Reviews Phage Therapy: A New Horizon in the Antibacterial Treatment of Oral Pathogens
Current Topics in Medicinal Chemistry Development of Magnesium Nanocomposites by Powder Metallurgy for Multifunctional Applications: Review
Current Nanomaterials Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy